

CURRENT CRU PROJECTS

IRBnet #	PRINCIPAL INVESTIGATORS	PROTOCOL DESCRIPTION	SPONSORS	RESEARCH TEAM Contacts
		Pediatric & Adolescent Infectious Disease/ Immunology Center		
915692	Joseph Domachowske, MD	A Phase 3, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine with Aluminum in Healthy Third-Trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in their Infants	Novavax, Inc.	Jodi Halczyn, CCRP 315-464-1992
939407	Joseph Domachowske, MD	A Phase 1/2, randomized, observer-blind, controlled, multi-center, dose-escalation study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals' respiratory syncytial virus (RSV) investigational vaccine based on the RSV viral proteins F, N and M2-1 encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A), when administered intramuscularly according to a 0, 1-month schedule to RSV-seropositive infants aged 12 to 23 months	Glaxo Smith Cline Biologicals	Kathie Contello, NP 315-464-5102
1125332	Manika Suryadevara, MD	A phase 2, randomized, DB, placebo-controlled study to evaluate the antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetics of orally administered Lumicitabine (JNJ-64041575), regimen in hospitalized infants and children aged 28 days to 36 months infected with RSV	Janssen	Kurtis Ahart, CCRP 315-464-6331
1006113	Manika Suryadevara, MD	A Prospective Study to Assess the Pediatric Respiratory Syncytial Virus (RSV) Electronic Severity and Outcome Rating System (PRESORS) and Clinical Endpoints in Neonates, Infants and Children less than or equal to 36 months of Age Hospitalized with RSV Infection	Janssen	Kurtis Ahart, CCRP 315-464-6331
1134702	Manika Suryadevara, MD	A Long-term Follow-up Study 64041575RSV2004 to evaluate the impact of Lumicitabine (JNJ-64041575) on the incidence of asthma and/or wheezing in Infants and children with a history of RSV	Janssen 2002	Kurtis Ahart, CCRP 315-464-6331